Literature DB >> 29300420

Lower 25-Hydroxyvitamin D Is Associated with Higher Relapse Risk in Patients with Relapsing-Remitting Multiple Sclerosis.

C Wang1, Z Zeng, B Wang, S Guo.   

Abstract

OBJECTIVES: To investigate the association between serum circulating 25-hydroxyvitamin D [25(OH) D] concentrations and exacerbation risk in Chinese patients with relapsing-remitting multiple sclerosis (RR-MS).
METHODS: From January 2014 to December 2014, consecutive RR-MS patients admitted to the Department of Neurology of our hospital were identified. Blood samples for 25(OH) D measurements were taken at admission. All included patients visited the outpatient clinic of our hospital 1 year after admission. The influence of serum 25[OH] D levels on exacerbation was performed by binary logistic regression analysis.
RESULTS: In this study, 109 patients finished the follow-up. Median follow-up time was 1 year (range 1.0-1.1). Twenty-one out of the 109 was at risk period for infection. A total of 32 patients experienced a total of 76 exacerbations during the study. In the follow-up, a total of 32 patients experienced exacerbations. Thus, the exacerbation rate was 29.4% (95%CI: 20.8%-37.9%). Exacerbation rates were found to decrease with increasing levels of serum 25-OH-D concentrations. For the quartiles category, the risk of an exacerbation was significantly increased in the group with first quartile compared to the group with fourth. Rate ratios for the first, second and third group were 4.2, 3.3 and 2.0, respectively (p for trend =0.011) when compared with the fourth group. Simultaneous evaluation of quartile categories of levels of serum 25(OH) D and infections showed that both factors were related to the exacerbation rate.
CONCLUSION: The data demonstrates that lower vitamin D status is a sign of more active disease in patients with RR-MS and suggests a beneficial effect of vitamin D on disease course in MS.

Entities:  

Keywords:  25-hydroxyvitamin D zzm321990; exacerbation risk; multiple sclerosis

Mesh:

Substances:

Year:  2018        PMID: 29300420     DOI: 10.1007/s12603-017-0894-3

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  35 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

3.  Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.

Authors:  Kristin I Løken-Amsrud; Trygve Holmøy; Søren J Bakke; Antonie Giaever Beiske; Kristian S Bjerve; Bård T Bjørnarå; Harald Hovdal; Finn Lilleås; Rune Midgard; Tom Pedersen; Jurate Saltyte Benth; Leiv Sandvik; Oivind Torkildsen; Stig Wergeland; Kjell-Morten Myhr
Journal:  Neurology       Date:  2012-06-13       Impact factor: 9.910

4.  Evolving expectations around early management of multiple sclerosis.

Authors:  Ralf Gold; Jerry S Wolinsky; Maria Pia Amato; Giancarlo Comi
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

5.  Vitamin D, invariant natural killer T-cells and experimental autoimmune disease.

Authors:  Margherita T Cantorna; Jun Zhao; Linlin Yang
Journal:  Proc Nutr Soc       Date:  2012-02       Impact factor: 6.297

6.  Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse.

Authors:  Elizabeth Regina Comini Frota; David Henrique Rodrigues; Eduardo Antonio Donadi; Doralina G Brum; Damacio Ramon Kaimen Maciel; Antônio Lúcio Teixeira
Journal:  Neurosci Lett       Date:  2009-05-27       Impact factor: 3.046

7.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

8.  Association of vitamin D and multiple sclerosis in India.

Authors:  Lekha Pandit; Sreeram V Ramagopalan; Chaithra Malli; Anitha D'Cunha; Ramya Kunder; Rajesh Shetty
Journal:  Mult Scler       Date:  2013-03-21       Impact factor: 6.312

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

10.  Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis.

Authors:  Joost Smolders; Mariëlle Thewissen; Evelyn Peelen; Paul Menheere; Jan Willem Cohen Tervaert; Jan Damoiseaux; Raymond Hupperts
Journal:  PLoS One       Date:  2009-08-13       Impact factor: 3.240

View more
  4 in total

1.  Editorial: Vitamin D: Does the Emperor Have No Clothes?

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

2.  Exonic variants of genes related to the vitamin D signaling pathway in the families of familial multiple sclerosis using whole-exome next generation sequencing.

Authors:  Vanesa Pytel; Jordi A Matías-Guiu; Laura Torre-Fuentes; Paloma Montero-Escribano; Paolo Maietta; Javier Botet; Sara Álvarez; Ulises Gómez-Pinedo; Jorge Matías-Guiu
Journal:  Brain Behav       Date:  2019-03-21       Impact factor: 2.708

Review 3.  Environmental Influencers, MicroRNA, and Multiple Sclerosis.

Authors:  Eiman Ma Mohammed
Journal:  J Cent Nerv Syst Dis       Date:  2020-01-20

4.  Factors associated with relapses in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.

Authors:  Yao Xie; Ziyu Tian; Fang Han; Shibing Liang; Ying Gao; Dahua Wu
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.